Julia Pezuk

Dr. Julia Pezuk


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2017 in Nanoscale
Verified
Journal Article
Open access
PDF file
MRMarcel I. Ramirez
Marcel I. Ramirez
MAMaria G. Amorim
Maria G. Amorim
CGCatarina Gadelha
Catarina Gadelha
IMIvana Milic
Ivana Milic
Joshua WelshJoshua Welsh
Joshua Welsh
EDEmmanuel Dias-Neto
Emmanuel Dias-Neto
Extracellular Vesicles (EVs) are gaining interest as central players in liquid biopsies, with potential applications in diagnosis, prognosis and therapeutic guidance in most pathological conditions.

1 March 2012 in Leukemia Research
Verified
Journal Article
Closed access
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
CSCarlos Alberto Scrideli
Carlos Alberto Scrideli
MBMaría Sol Brassesco
María Sol Brassesco
AMAndressa Gois Morales
Andressa Gois Morales
JPJulia Pezuk
Julia Pezuk
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone

26 July 2013 in Cancer Gene Therapy
Verified
Journal Article
Open access
PDF file
JPJulia Pezuk
Julia Pezuk
MBMaría Sol Brassesco
María Sol Brassesco
AMA G Morales
A G Morales
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
RQR G de Paula Queiroz
R G de Paula Queiroz
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone
Glioblastoma (GBM) is one of the most aggressive central nervous system tumors with a patient’s median survival of <1 year. Polo-like kinases (PLKs) are a family of serine/threonine kinases that have key roles in cell cycle control and DNA-damage response. We evaluated PLK1, 2, 3 and 4 gene expression in 8 GBM cell lines and 17 tumor samples, and analyzed the effect of the PLK1 inhibition on SF188 and T98G GBM cell lines and 13 primary cultures. Our data showed PLK1 overexpression and a variable altered expression of PLK2, 3 and 4 genes in GBM tumor samples and cell lines. Treatments with nanomolar concentrations of BI 2536, BI 6727, GW843682X or GSK461364 caused a significant decrease in GBM cells proliferation. Colony formation was also found to be inhibited (P<0.05), whereas apoptosis rate and mitotic index were significantly increased (P<0.05) after PLK1 inhibition in both GBM cell lines. Cell cycle analysis showed an arrest at G2 (P<0.05) and cell invasion was also decreased after PLK1 inhibition. Furthermore, simultaneous combinations of BI 2536 and temozolomide produced synergistic effects for both the cell lines after 48 h of treatment. Our findings suggest that PLK1 might be a promising target for the treatment of GBMs.

6 July 2021 in Einstein (São Paulo)
Verified
Journal Article
Open access
AJAriany Lima Jorge
Ariany Lima Jorge
EPErik Ribeiro Pereira
Erik Ribeiro Pereira
COChristian Sousa de Oliveira
Christian Sousa de Oliveira
EFEduardo dos Santos Ferreira
Eduardo dos Santos Ferreira
EMEdmara Toledo Ninzoli Menon
Edmara Toledo Ninzoli Menon
JPJulia Pezuk
Julia Pezuk
MicroRNAs are small RNA molecules that regulate gene expression in cells. These small molecules comprise 17 to 25 nucleotides and are able to recognize target messenger RNAs by sequence complementarity and regulate their protein translation. Different microRNAs are expressed in all human cells. There is over 2,500 microRNAs described in humans that are involved in virtually all biological processes. Given their role as gene expression regulators, these molecules have been widely investigated and are thought to be associated with some specific physiological and pathological conditions, being proposed as biomarkers. It has recently been reported that microRNAs are secreted outside cells and are involved in intercellular communication. MicroRNAs in biological fluids are named circulating and have been detected in all body fluids, although the expression profile is specific for each type. The major advantages of using circulating microRNAs as biological markers are the high stability of those molecules and the wide availability of samples. Also, given the individual nature of microRNA expression changes, these molecules have a high potential for use in personalized medicine. In fact, microRNA expression profile determination may support disease recognition and diagnosis, and can be used to monitor therapeutic responses and establish patient prognosis, assisting in choice of treatment. This review provides a general overview of microRNAs and discusses the importance of those molecules in cancer, for deeper understanding of their role in this disease.

2 June 2013 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
AMAndressa Gois Morales
Andressa Gois Morales
JPJulia Pezuk
Julia Pezuk
MBMaría Sol Brassesco
María Sol Brassesco
Jaqueline Carvalho de OliveiraJaqueline Carvalho de Oliveira
Jaqueline Carvalho de Oliveira
RQRosane Gomes de Paula Queiroz
Rosane Gomes de Paula Queiroz
LTLuiz Gonzaga Tone
Luiz Gonzaga Tone

1 October 2020 in Pharmacological Research
Verified
Journal Article
Closed access
GSGraziella Sousa
Graziella Sousa
GVGabriela Maciel Vieira
Gabriela Maciel Vieira
PCPablo Ferreira das Chagas
Pablo Ferreira das Chagas
JPJulia Pezuk
Julia Pezuk
MBMaría Sol Brassesco
María Sol Brassesco